Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.43 |
| ▸ | LPL | P06858 | 12/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30404611 | 0.94 | LIPG (0.46) | LIPGLPLROCK1IRAK4BACE1 | |
| SCHEMBL24175626 | 0.94 | LIPG (0.46) | LIPGLPLROCK1IRAK4BACE1 | |
| SCHEMBL28843389 | 0.78 | LIPG (0.46) | LIPGLPLROCK1IRAK4BACE1 | |
| SCHEMBL29933385 | 0.78 | LIPG (0.46) | LIPGLPLROCK1IRAK4BACE1 | |
| SCHEMBL24174506 | 0.78 | LIPG (0.43) | LIPGLPLROCK1IRAK4BACE1 | |
| SCHEMBL23414976 | 0.76 | LPL (0.49) | LIPGLPLP2RX7CA1CA2 | |
| SCHEMBL1476213 | 0.76 | LIPG (0.59) | LIPGLPLIRAK4EGFRCA1 | |
| SCHEMBL26980490 | 0.75 | LPL (0.39) | LIPGLPLROCK1IRAK4EGFR | |
| SCHEMBL2588245 | 0.75 | LPL (0.43) | LIPGLPLIRAK4 | |
| SCHEMBL12189121 | 0.75 | LIPG (0.43) | LIPGLPLROCK1IRAK4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-16 | — | — | US | disclosed |
| EP-3917527-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113645971-A | Compound and use thereof | 福宏治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | LIPG 2836/4885LPL 1810/4885ROCK1 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.